BRPI0908217A2 - Uso de compostos de ligação aos ligantes do receptor sigma para o tratamento de dor neuropática desenvolvida como uma consequência de quimioterapia - Google Patents

Uso de compostos de ligação aos ligantes do receptor sigma para o tratamento de dor neuropática desenvolvida como uma consequência de quimioterapia

Info

Publication number
BRPI0908217A2
BRPI0908217A2 BRPI0908217-4A BRPI0908217A BRPI0908217A2 BR PI0908217 A2 BRPI0908217 A2 BR PI0908217A2 BR PI0908217 A BRPI0908217 A BR PI0908217A BR PI0908217 A2 BRPI0908217 A2 BR PI0908217A2
Authority
BR
Brazil
Prior art keywords
chemotherapy
consequence
treatment
ligand binding
neuropathic pain
Prior art date
Application number
BRPI0908217-4A
Other languages
English (en)
Inventor
José Manuel Baeyens-Cabrera
Helmut H Buschmann
José-Miguel Vela-Hernandez
Daniel Zamanillo-Castanedo
Francisco Rafael Nieto-López
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08384001A external-priority patent/EP2090311A1/en
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of BRPI0908217A2 publication Critical patent/BRPI0908217A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0908217-4A 2008-02-18 2009-02-17 Uso de compostos de ligação aos ligantes do receptor sigma para o tratamento de dor neuropática desenvolvida como uma consequência de quimioterapia BRPI0908217A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08384001A EP2090311A1 (en) 2008-02-18 2008-02-18 Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy
EP08008682 2008-05-08
PCT/EP2009/001109 WO2009103487A1 (en) 2008-02-18 2009-02-17 Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy

Publications (1)

Publication Number Publication Date
BRPI0908217A2 true BRPI0908217A2 (pt) 2015-08-25

Family

ID=40790823

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908217-4A BRPI0908217A2 (pt) 2008-02-18 2009-02-17 Uso de compostos de ligação aos ligantes do receptor sigma para o tratamento de dor neuropática desenvolvida como uma consequência de quimioterapia

Country Status (16)

Country Link
US (2) US20110052723A1 (pt)
EP (1) EP2254579B1 (pt)
JP (1) JP5859207B2 (pt)
KR (1) KR20110008166A (pt)
CN (1) CN101951908A (pt)
AU (1) AU2009217031B2 (pt)
BR (1) BRPI0908217A2 (pt)
CA (1) CA2712640A1 (pt)
DK (1) DK2254579T3 (pt)
ES (1) ES2665042T3 (pt)
HU (1) HUE036546T2 (pt)
MX (1) MX2010009026A (pt)
PL (1) PL2254579T3 (pt)
PT (1) PT2254579T (pt)
RU (1) RU2537226C2 (pt)
WO (1) WO2009103487A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
GB0907973D0 (en) * 2009-05-08 2009-06-24 Modern Biosciences Plc Combination therapy
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
WO2012064150A2 (ko) * 2010-11-11 2012-05-18 한국생명공학연구원 벤프로페린 유도체를 유효성분으로 함유하는 혈관신생-관련 질환의 예방 및 치료용 조성물
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
DK2857037T3 (da) * 2012-05-31 2019-07-22 Univ Kinki Middel til forebyggelse og/eller behandling af perifere neuropatiske smerter forårsaget af anticancerlægemiddel
RU2506077C1 (ru) * 2013-01-25 2014-02-10 Общество С Ограниченной Ответственностью "Валента-Интеллект" Комбинация для профилактики, коррекции и терапии боли, связанной с нейродегенерацией или ассоциированной с соматоформными расстройствами
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
JP6591431B2 (ja) * 2014-03-04 2019-10-16 ザ ユニヴァーシティー オブ ミシシッピ 侵害受容処理並びに記憶障害及び認知異常の病態生理学的研究におけるプローブとして高度に選択的なシグマ受容体リガンド及び放射性リガンド
WO2015135947A1 (en) * 2014-03-10 2015-09-17 Universite D'aix-Marseille Piperazine phenothiazine derivatives for treating spasticity
EP2985036A3 (en) * 2014-08-14 2016-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. CYP2J2 antagonists in the treatment of pain
JP6851639B2 (ja) 2015-07-16 2021-03-31 ゾミクス バイオファーマ， インコーポレイテッド プラチナ薬剤の毒性の予防方法
EP3415143A1 (en) * 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexine for the treatment of pain
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
CA3112679A1 (en) 2018-09-28 2020-04-02 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
KR20200046525A (ko) * 2018-10-24 2020-05-07 건국대학교 글로컬산학협력단 피렌페론 화합물을 유효성분으로 포함하는 취약 x 증후군 및 관련 발달 장애치료용 조성물
EP4302779A1 (en) * 2021-03-04 2024-01-10 Socium Inc. Cancer therapeutic agent
KR102942263B1 (ko) * 2021-11-05 2026-03-23 건국대학교 글로컬산학협력단 하이칸톤을 포함하는 우울장애 또는 신경염증질환의 예방 또는 치료용 조성물
US20250288591A1 (en) * 2022-05-02 2025-09-18 Undaunted Bio, Inc. Trimeprazine for use in treating trigeminal neuralgia and for reducing pain related thereto
KR20260108590A (ko) * 2023-11-01 2026-07-08 언던티드 바이오 인코포레이티드 삼차신경통과 연관된 통증 치료에서 사용하기 위한 트리메프라진

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191496B1 (pl) * 1997-07-02 2006-05-31 Merck & Co Inc Odmiana polimorficzna 2-(R)-{1-(R) -[3,5-bis(trifluorometylo)-fenylo]etoksy} -3-(S)-(4-fluoro) fenylo-4-[3-(5-okso-1H,4H-1,2,4-triazolo)metylo] morfoliny, sposób jej wytwarzania, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
RU2218187C2 (ru) * 2002-02-11 2003-12-10 Ростовский научно-исследовательский онкологический институт Способ лечения болевого синдрома у онкологических больных
GB0206505D0 (en) * 2002-03-19 2002-05-01 Euro Celtique Sa Pharmaceutical combination
EP1635805A4 (en) * 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
EP1781272B1 (en) 2004-07-24 2017-09-06 Laboratorios Del Dr. Esteve, S.A. Use of compounds active on the sigma receptor for the treatment of mechanical allodynia
KR101352012B1 (ko) * 2004-08-27 2014-01-15 라보라토리오스 델 드라. 에스테브.에스.에이. 시그마 수용체 저해제
US20090325975A1 (en) 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1761071A1 (de) * 2005-08-29 2007-03-07 Stueckler Gerd Verfahren zur Aufnahme eines Bildes und Digitalkamera
WO2007110221A1 (en) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy

Also Published As

Publication number Publication date
US20110052723A1 (en) 2011-03-03
PL2254579T3 (pl) 2018-08-31
DK2254579T3 (en) 2018-04-09
PT2254579T (pt) 2018-04-16
ES2665042T3 (es) 2018-04-24
WO2009103487A1 (en) 2009-08-27
MX2010009026A (es) 2010-09-24
JP2011512338A (ja) 2011-04-21
AU2009217031A1 (en) 2009-08-27
RU2010138634A (ru) 2012-03-27
CN101951908A (zh) 2011-01-19
EP2254579B1 (en) 2018-01-10
JP5859207B2 (ja) 2016-02-10
EP2254579A1 (en) 2010-12-01
AU2009217031B2 (en) 2013-12-19
RU2537226C2 (ru) 2014-12-27
KR20110008166A (ko) 2011-01-26
HUE036546T2 (hu) 2018-07-30
US20170112829A1 (en) 2017-04-27
CA2712640A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
PL2254579T3 (pl) Zastosowanie związków wiążących się do ligandów receptora sigma do leczenia bólu neuropatycznego powstającego w konsekwencji chemioterapii
BRPI0814994A2 (pt) Métodos químicos para tratamento de uma matéria-prima de metátese
BRPI0910282A2 (pt) Composto oxadiazo-antraceno para o tratamento de diabetes
BRPI0814157A2 (pt) Composição de catalisador e processos para a preparação e uma composição de catalisador e para desalquilação de etil-benzeno
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0810139A2 (pt) Catalisador para a preparação de metil mercaptano
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
PT2515855E (pt) Terapêutica de combinação para dpoc
BRPI0820054A2 (pt) Uso de bactérias para a produção de bioenergia
EP2575790A4 (en) STABILIZED CHEMICAL COMPOSITION
BRPI0812040A2 (pt) Indicações para terapia de anti-il-i-beta
BRPI0922884A2 (pt) compostos para tratamento de câncer
BR112012004080A2 (pt) composições farmacêuticas para tratar ibd
BRPI0820677A2 (pt) Misturas de compostos pesticidas
LT2448666T (lt) Lakiųjų organinių junginių, gaunamų iš organinių medžiagų, adsorbcija
BRPI0815947A2 (pt) misturas de gipsita para formar sólidos
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0812144A2 (pt) Recipiente para substâncias voláteis
BRPI0921210A2 (pt) processos para a preparação de compostos de arilaminas
BRPI0920728A2 (pt) Composição estabilizada para tratamento de psoríase
BRPI0821567A2 (pt) Misturas de compostos pesticidas
BRPI0820650A2 (pt) Misturas de compostos pesticidas
FI20080112A0 (fi) Seos
BR112012000561A2 (pt) cartucho de múltiplos componentes para uso único.
BRPI0912679A2 (pt) composição farmacêutica para o tratamento de fibromialgia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2553 DE 10/12/2019.